Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal

Executive Summary

Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.

You may also be interested in...

P&U/Searle Mingling Sales Forces To Promote Detrol In Advance Of Merger

Searle and Pharmacia & Upjohn are getting a head start on their proposed merger through a co-promotion deal for P&U's overactive bladder therapy Detrol.

Celebrex Data Requested By FDA May Clarify Cancer Risk Reduction Potential

FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.

Monsanto/P&U Aggregation Hinges On Ag Business: Pull Of Pooling?

Monsanto's proposed merger of equals with Pharmacia & Upjohn hinges upon convincing shareholders that there is value in delaying the unlocking of Monsanto's ag business from the Searle pharmaceutical business.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts